Korsnes JS, Goodwin BB, Murray M, Candrilli SD. Antiretroviral treatment switching and its association with economic outcomes and adverse treatment effects among commercially insured and Medicaid-enrolled patients with HIV in the United States. Ann Pharmacother. 2016 Dec;50(12):989-1000.
Amend KL, Landon J, Thyagarajan (Hoffman) V, Niemcryk S, McAfee A. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann Pharmacother. 2011 Oct;45(10):1230-9. doi: 10.1345/aph.1Q110
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Prevalence and impact of antidepressant-associated sexual dysfunction in three European countries: replication in a cross-sectional patient survey. J Psychopharmacol. 2010 Apr 1;24(4):489-96.
Novick D, Reed C, Gonzalez-Pinto A, Aguado J, Haro JM. Comparison of olanzapine and valproate over 12 months of treatment in the emblem study. J Psychopharmacol. 2010;24:A54.
Nau DP, Steinke DT, Williams LK, Austin R, Lafata JE, Divine G, Pladevall-Vila M. Adherence analysis using visual analog scale versus claims-based estimation. Ann Pharmacother. 2007 Nov;41(11):1792-7.
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS. Antidepressant-induced sexual dysfunction in three European countries: prevalence and impact in a cross-sectional survey replication. J Psychopharmacol. 2007;21(Suppl):A39.
Fireman B, Mines D, Lee J, Hunkeler EM. The risk of suicide in patients treated with venlafaxine, fluoxetine, citalopram, or paroxetine at Kaiser Permanente in Northern California. Poster presented at the 2006 Summer Meeting of the British Association for Psychopharmacology; July 2006. Oxford, United Kingdom. [abstract] J Psychopharmacol. 2006 Sep; 20(5 Suppl):A58.